Voizmed Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 04-07-2024
- Paid Up Capital ₹ 1.00 M
as on 04-07-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 17.98%
(FY 2023)
- Profit 77.44%
(FY 2023)
- Ebitda 73.16%
(FY 2023)
- Net Worth 83.02%
(FY 2023)
- Total Assets 9.68%
(FY 2023)
About Voizmed Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Neeraj Giri and Arvind Sharma serve as directors at the Company.
- CIN/LLPIN
U52609HR2019PTC078946
- Company No.
078946
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Mar 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Panchkula, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Voizmed Pharma Private Limited offer?
Voizmed Pharma Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Pre & Probiotic Capsule, Nutraceuticals & Dietary Supplements, Dietary Supplements, Anti Infective Drugs & Medicines, Antifungal Cream, Ointment & Powder, Pharma & Bioanalytical Services, PCD Pharma Franchise, Mineral Supplement, Antacid Drugs.
Who are the key members and board of directors at Voizmed Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neeraj Giri  | Director | 06-Mar-2019 | Current |
| Arvind Sharma | Director | 06-Mar-2019 | Current |
Financial Performance of Voizmed Pharma.
Voizmed Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 17.98% increase. The company also saw a substantial improvement in profitability, with a 77.44% increase in profit. The company's net worth Soared by an impressive increase of 83.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Voizmed Pharma?
In 2023, Voizmed Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Voizmed Pharma?
Unlock and access historical data on people associated with Voizmed Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Voizmed Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Voizmed Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
